ERBB2 and breast cancer: Because Luminal A has the best prognosis of all breast cancer subtypes71, we compared the log intensity of Nek2 mRNA expression in several breast cancer subtypes relative to Luminal A. This analysis indicates that Nek2 levels are significantly higher in Basal, Her2+, Luminal B, and Claudin-Low relative to Luminal A (Supp.